Loading Events

ASLAN Pharmaceuticals Virtual KOL Event – Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market

Banners (74)
DATE: May 7, 2024

About The Event

Join ASLAN Pharmaceuticals for a virtual KOL Event with Lisa Beck, MD from University of Rochester, Peter Lio, MD from Northwestern University, and Raj Chovatiya, MD, PhD from Rosalind Franklin University Chicago Medical School, moderated by Seth Orlow, MD, PhD from New York University, in a discussion of the recently announced positive interim results from ASLAN’s Phase 2 TREK-DX study of eblasakimab, a potential first-in-class biologic candidate, in patients with moderate-to-severe atopic dermatitis (AD) that had previously been treated with dupilumab. Panelists will discuss this growing new market and the treatment options available to patients with an inadequate response to dupilumab. Company management will also present new data from the interim analysis of the TREK-DX study.

Eblasakimab is a novel monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. Interim data from TREK-DX, a first-of-its-kind study of dupilumab-experienced AD patients, shows eblasakimab may have the potential to be highly effective in AD patients even if dupilumab has not been.

A live question and answer session will follow the formal presentation